It was demonstrated that patients with ER-positive/PR-positive BCs were more likely to benefit from endocrine therapy than those with ER-positive/PR-negative tumours (Nordenskjöld et al. 2016; Bardou et al. 2003). Here, ESR1 is linked to neoplasm.